Early experience of seven hepatocellular carcinoma cases treated with regorafenib

Regorafenib became second‐line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier.

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Case Rep
Asıl Yazarlar: Uchikawa, Shinsuke, Kawaoka, Tomokazu, Aikata, Hiroshi, Kodama, Kenichiro, Inagaki, Yuki, Hatooka, Masahiro, Morio, Kei, Nakahara, Takashi, Murakami, Eisuke, Hiramatsu, Akira, Tsuge, Masataka, Imamura, Michio, Kawakami, Yoshiiku, Chayama, Kazuaki
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Case Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6230610/
https://ncbi.nlm.nih.gov/pubmed/30455925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1791
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller